RxSight (RXST) Scheduled to Post Earnings on Monday

RxSight (NASDAQ:RXST) is scheduled to announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. RxSight has set its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

RxSight (NASDAQ:RXST) last posted its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company had revenue of $28.58 million for the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RxSight Stock Performance

RXST stock opened at $61.68 on Friday. RxSight has a one year low of $18.09 and a one year high of $61.85. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -43.13 and a beta of 1.21. The firm has a 50-day simple moving average of $52.73 and a two-hundred day simple moving average of $42.81.

Analysts Set New Price Targets

Several analysts have recently commented on RXST shares. JPMorgan Chase & Co. increased their price objective on RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Stifel Nicolaus increased their price target on RxSight from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of RxSight in a report on Thursday, April 11th. Finally, Oppenheimer upped their price objective on shares of RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $49.63.

Insider Activity

In related news, CFO Shelley B. Thunen sold 9,125 shares of RxSight stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $47.02, for a total transaction of $429,057.50. Following the completion of the sale, the chief financial officer now owns 13,691 shares of the company’s stock, valued at $643,750.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other RxSight news, CFO Shelley B. Thunen sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $49.90, for a total value of $998,000.00. Following the sale, the chief financial officer now directly owns 8,402 shares of the company’s stock, valued at $419,259.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Shelley B. Thunen sold 9,125 shares of RxSight stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $47.02, for a total value of $429,057.50. Following the transaction, the chief financial officer now owns 13,691 shares of the company’s stock, valued at approximately $643,750.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,490 shares of company stock valued at $3,043,578. Company insiders own 21.13% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.